Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Releases Data From Four Phase 3 POLARIS Studies Evaluating Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients

Source Link:
http://www.gilead.com/news/press-releases/2016/10/gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-oncedaily-fixeddose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatmentna%C3%AFve-and-treatmentexperienced-genotype-16-chronic-hcvinfected-patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 20, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Polaris 1, Polaris 2, Polaris 3, Polaris 4, Sofosbuvir, Velpatasvir, Voxilaprevir, Treatment-experienced, Genotype 1-6, Chronic Hcv
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.